CN113413375A - 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 - Google Patents
皮肤多种损伤创面治疗的外用药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN113413375A CN113413375A CN202110817611.5A CN202110817611A CN113413375A CN 113413375 A CN113413375 A CN 113413375A CN 202110817611 A CN202110817611 A CN 202110817611A CN 113413375 A CN113413375 A CN 113413375A
- Authority
- CN
- China
- Prior art keywords
- composition
- wound
- skin
- volume
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 107
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- 238000002360 preparation method Methods 0.000 title description 26
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 323
- 206010052428 Wound Diseases 0.000 claims abstract description 313
- 208000034656 Contusions Diseases 0.000 claims abstract description 7
- 230000009519 contusion Effects 0.000 claims abstract description 6
- 208000025865 Ulcer Diseases 0.000 claims abstract description 5
- 231100000397 ulcer Toxicity 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 135
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 65
- 239000008194 pharmaceutical composition Substances 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 229960004063 propylene glycol Drugs 0.000 claims description 35
- 239000004863 Frankincense Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 23
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 22
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 22
- 235000006226 Areca catechu Nutrition 0.000 claims description 21
- 229960003639 laurocapram Drugs 0.000 claims description 20
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 claims description 17
- 240000007551 Boswellia serrata Species 0.000 claims description 17
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 16
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 16
- 240000007311 Commiphora myrrha Species 0.000 claims description 16
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 16
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 16
- 206010053615 Thermal burn Diseases 0.000 claims description 16
- VARQGBHBYZTYLJ-UHFFFAOYSA-N tricosan-12-one Chemical compound CCCCCCCCCCCC(=O)CCCCCCCCCCC VARQGBHBYZTYLJ-UHFFFAOYSA-N 0.000 claims description 16
- 206010063560 Excessive granulation tissue Diseases 0.000 claims description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 14
- 240000004824 Trimezia steyermarkii Species 0.000 claims description 14
- 239000009136 dragon's blood Substances 0.000 claims description 14
- 210000001126 granulation tissue Anatomy 0.000 claims description 14
- 241000563984 Ampelopsis Species 0.000 claims description 13
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 241001313857 Bletilla striata Species 0.000 claims description 12
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 12
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 12
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 12
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 12
- 235000011477 liquorice Nutrition 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 10
- 244000235603 Acacia catechu Species 0.000 claims description 9
- 244000170916 Paeonia officinalis Species 0.000 claims description 9
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 9
- 241000123835 Ampelopsis japonica Species 0.000 claims description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 8
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 8
- 241000717739 Boswellia sacra Species 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 241000972673 Phellodendron amurense Species 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 235000002710 Ilex cornuta Nutrition 0.000 claims description 6
- 241001310146 Ilex cornuta Species 0.000 claims description 6
- 241001057584 Myrrha Species 0.000 claims description 6
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 6
- 239000009286 sanguis draxonis Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229960005091 chloramphenicol Drugs 0.000 claims description 5
- 229960002518 gentamicin Drugs 0.000 claims description 5
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 4
- 244000111489 Gardenia augusta Species 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010060976 Bacillus infection Diseases 0.000 claims description 3
- 206010040943 Skin Ulcer Diseases 0.000 claims description 3
- 206010072170 Skin wound Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010040872 skin infection Diseases 0.000 claims description 3
- 231100000019 skin ulcer Toxicity 0.000 claims description 3
- 208000004221 Multiple Trauma Diseases 0.000 claims 2
- 208000023637 Multiple injury Diseases 0.000 claims 2
- 244000247747 Coptis groenlandica Species 0.000 claims 1
- 240000002045 Guettarda speciosa Species 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940107666 astragalus root Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 42
- 230000035876 healing Effects 0.000 abstract description 32
- 239000007788 liquid Substances 0.000 abstract description 32
- 230000001737 promoting effect Effects 0.000 abstract description 29
- 208000015181 infectious disease Diseases 0.000 abstract description 21
- 241000894006 Bacteria Species 0.000 abstract description 14
- 230000006378 damage Effects 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 230000002829 reductive effect Effects 0.000 abstract description 8
- 206010030113 Oedema Diseases 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 208000034693 Laceration Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 79
- 206010039509 Scab Diseases 0.000 description 71
- 235000011187 glycerol Nutrition 0.000 description 41
- 210000004369 blood Anatomy 0.000 description 39
- 239000008280 blood Substances 0.000 description 39
- 229940079593 drug Drugs 0.000 description 35
- 230000036407 pain Effects 0.000 description 25
- 208000028990 Skin injury Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 230000008961 swelling Effects 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 13
- 230000003179 granulation Effects 0.000 description 13
- 238000005469 granulation Methods 0.000 description 13
- 231100000241 scar Toxicity 0.000 description 13
- 244000080767 Areca catechu Species 0.000 description 12
- 235000006533 astragalus Nutrition 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 12
- 210000000416 exudates and transudate Anatomy 0.000 description 11
- 241000037740 Coptis chinensis Species 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- 208000033809 Suppuration Diseases 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 230000001338 necrotic effect Effects 0.000 description 9
- 238000010926 purge Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000003128 head Anatomy 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 244000061520 Angelica archangelica Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 6
- 241000382455 Angelica sinensis Species 0.000 description 6
- 241001061264 Astragalus Species 0.000 description 6
- 241000045403 Astragalus propinquus Species 0.000 description 6
- 240000001972 Gardenia jasminoides Species 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000004233 talus Anatomy 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 240000001624 Espostoa lanata Species 0.000 description 5
- 235000009161 Espostoa lanata Nutrition 0.000 description 5
- 206010048038 Wound infection Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000001624 hip Anatomy 0.000 description 5
- 210000003739 neck Anatomy 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 208000032544 Cicatrix Diseases 0.000 description 4
- 206010051814 Eschar Diseases 0.000 description 4
- 235000018958 Gardenia augusta Nutrition 0.000 description 4
- 206010021531 Impetigo Diseases 0.000 description 4
- 241000972672 Phellodendron Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 231100000333 eschar Toxicity 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 241000218202 Coptis Species 0.000 description 3
- 244000301850 Cupressus sempervirens Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- UCZJPQIEFFTIEV-UHFFFAOYSA-N 5-methoxy-6-methyl-2-phenylchromen-7-one Chemical compound C=1C=C2C(OC)=C(C)C(=O)C=C2OC=1C1=CC=CC=C1 UCZJPQIEFFTIEV-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000002389 essential drug Substances 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- -1 flavonoid compounds Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000002640 perineum Anatomy 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000016952 Ear injury Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 235000003366 Ilex purpurea Nutrition 0.000 description 1
- 241001100935 Ilex purpurea Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000001519 Verbena officinalis Species 0.000 description 1
- 235000018718 Verbena officinalis Nutrition 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- BGLUXFNVVSVEET-UHFFFAOYSA-N beta-angelica lactone Chemical compound CC1OC(=O)C=C1 BGLUXFNVVSVEET-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002283 diesel fuel Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 239000005341 toughened glass Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明涉及一种治疗皮肤多种损伤创面的液态外用药物组合物。该组合物的特征在于具有很强的吸湿保湿性,能快速地封闭创面。该组合物可抗氧化、有效地抑菌灭菌、保护创面的生发细胞免受进一步损害,消除创面水肿,促进创面愈合。该药物组合物可广泛地用于治疗烧伤、皮肤擦挫伤、割裂伤、感染性皮肤疮疡创面的暴露治疗,节省敷料,使用方便、高效。
Description
技术领域
本发明涉及一种用于人类皮肤多种损伤创面治疗的液态外用药物组合物。使用这种组合物,其特点在于能快速有效地封闭创面,消除创面水肿,减少、停止创面的渗出,药物组合物与创面已有的渗出液结合形成透明薄痂,能保护创面基底及周围有生命力的细胞免受进一步的损伤,消除创面感染,促进创面痂下愈合,最大限度地减少瘢痕的形成。本发明属于中西医结合外科领域。
背景技术
人类皮肤各种损伤创面的修复愈合,是复杂的病理生理过程,轻微细小的损伤创面,经历伤后创面出血或渗出、干燥结痂、痂下愈合。大多数比较大或特殊皮损(如烧伤)创面,在损伤后创面要经历渗出、感染、坏死组织清除、感染得到控制、创面渗出减少、结痂或创面被生物材料覆盖、创面逐渐瘢痕愈合。
在皮肤损伤创面复杂的愈合过程中,除全身性治疗用药外,创面处理的一个重要环节就是创面用药的选择。目前,用于皮肤损伤创面治疗的药物制剂繁多,大致可分为水粉剂、油膏剂、消毒剂、成膜剂。本领域的技术人员都能体会到,在临床皮肤损伤创面的治疗中,以上这几类创面用药虽然都有疗效,但也都存在某些局限性。
如上所述,在治疗皮肤损伤创面目前可选用的药物制剂中,如用水粉剂,要用大量的敷料包扎创面,药剂中的水分干燥后,敷料往往与创面发生粘连,在更换敷料时,会撕伤创面的新生组织导致出血,病人疼痛难忍,且更换敷料时间长,医务人员工作量大。如用油膏剂,油膏与创面渗液不相溶,在创面渗液较多的情况下,油膏易流淌,也会造成敷料与创面粘连的现象,给更换敷料造成困难。成膜喷雾剂,虽较好地封闭创面,但没有很好地解决吸纳创面渗液,容易产生膜下积脓。
中医认为,“河流萌护草木,气血萌护肌肤”。就像草木离不开水土一样,肌肤损伤创面的修复要有人体气血的充足供养。中药黄芪、当归、丹参、赤芍益气活血,消肿止痛,气血行则肌肤生。
黄连、黄芩、黄柏、栀子系古代名方黄连解毒汤,出自东晋葛洪《肘后备急方》和唐代王焘《外台秘要方》,后世医家用于治疗各种疮疡火毒内服。近现代医籍杂志中屡见将黄连、黄芩、黄柏用麻油煎或调后涂治烧烫伤创面。诸痛痒疮皆属于心,黄芩泻上焦肺火,黄连泻上中焦心胃之火,黄柏泻下焦相火,《药品化义》中说,黄柏能降火自顶至踵,从皮肤到骨髓,无不周到,栀子通降三焦之火。这样周身之火毒能够降本流末,就不会再往外爆疮了。现代研究发现本方有抗炎抑菌作用,有降解内毒素调节免疫功能的作用,有保护脑、肝、肾、肠粘膜血管及抗细胞凋亡的作用,有抗凝血、抗血栓形成的作用。
白蔹清热解毒,四季青既清热解毒,又收湿敛疮,还凉血止血,白芨收湿敛疮,甘草调和诸药,解毒抗炎,与黄芪、当归、丹参、赤芍一起,对创面组织活细胞有营养作用。
乳香偏于行气通窍,没药偏于理血化瘀,乳香、没药辛香发散,乃驱逐气滞血瘀之要药。大疮都可以靠气通血活消除肿胀,促进局部损伤的修复。乳香、没药的消肿生肌的作用是一般药物难以取代的。
血竭除血痛,乃和血之圣药,专攻血分、力专效宏,而乳香、没药虽主血病、兼入气分。血竭为散瘀血、生新血之要药,主破积血、疗金疮、止疼痛,单用也能立竿见影,与乳香、没药联用,属强强联合、活血逐瘀之功更大。血止不留瘀、活血能止痛,所以这三味药为血家三剑客,哪里有瘀血阻滞,它们剑锋所指,无不血活痛止。儿茶除抗菌收敛的作用外,尚有去痂作用。
传统中医文献记载的疮疡科治疗用的药材有几十种,上述十六种中药材只是散在地出现在各种处方中。只用作制备汤、散(粉)、膏剂的组分。这几种剂型治疗烧伤创面的局限性已如前所述。
事实上,理想的创面用药应该具有镇痛、快速地封闭创面、吸收创面渗液、减少渗出、利于引流、能保护创面、促进创面上皮细胞生长、抗菌谱广且作用强、不产生或少产生耐药菌株、无毒性、副作用少、创面愈合后瘢痕少等特点。因此本发明所要解决的课题即寻找一种使用方便、高效的治疗皮肤多种损伤创面的液态外用药物组合物,其中使用重要原料药加之中西结合思路,以不同既往的构思,用特定的方法制备该药物组合物,尽量满足理想的创面用药应具备的条件。
发明内容
本申请书首先强调本发明药物组合物的重要组分是由丙三醇,1,2丙二醇,水溶性月桂氮酮或癸基甲基亚砜和水按特定配比组成。该重要组分在治疗皮肤多种皮肤损伤创面时,单独使用能快速封闭创面,吸收创面渗液,形成透明薄痂,抵御外部细菌的侵入,而与精选的药物组方精妙地结合,就能呈现许多理想的治疗效果!这个重要的组分及其特定的配比,是本发明的最大特征。
人体是一个外周全部被皮肤覆盖的有机体,通过血液循环和体液的交换,使构成机体的最小单位即每个活细胞在完全封闭的相对恒定的环境下与外界进行物质交换,实现新陈代谢,维持生命的运转。皮肤因多种原因造成损伤,就会造成被皮肤保护的损伤部位的组织细胞外露,损伤的局部出现“灾难”,机体就会动员有限的力量到达伤部“抢险救灾”,由此伤部出现一系列病理生理演变,机体能动员的防御力量有限,创面较大,不得不依靠外援——药物。作为医生,面对皮肤多种损伤创面,首先使创面快速地恢复完全封闭状态,与周围空气隔绝,进而逆转创面的病理变化,如止血、止渗、消肿、灭菌,促进创面生理修复,皮肤多种损伤创面才能顺利地度过“灾难”,而恢复常态。这里提出“对皮肤多种损伤创面治疗第一要务是快速完全地封闭创面”,这一论述在现有文献中均未见强调,而本发明人正是对这一论述进行透彻的观察与思考,才认真反复实践,找到并选用丙三醇,1,2丙二醇,水溶性月桂氮酮和少量水按特定配比作为本发明药物组合物的基础药阵,配合精选的中药材组成药物组合物,淋漓尽致地挖掘发挥构成基础药阵四种物质的功能,达成本发明。皮肤多种损伤创面,不能再涂敷有明显刺激的药物而造成创面组织细胞再损伤。本发明选用的这个基础药阵不但能满足上述要求,而且还能提取中药材的药用有效成分,达到吸水湿、止渗液、促渗透、结薄痂、活气血、通脉络、供营养、促新生。这些都是创面尽快愈合,减少瘢痕的有利举措。
本发明公开了一种治疗皮肤多种损伤创面的药物组合物,其中,所述药物组合物的重要组分包括丙三醇、1,2丙二醇、水溶性月桂氮酮或癸基甲基亚砜、以及水按特定配比组成,其中所述丙三醇占组合物的含量为80-90体积%。
在一些实例中,所述1,2丙二醇占组合物的含量为6-15体积%;所述水溶性月桂氮酮占组合物的含量为0.2-2体积%,优选含量为0.6-1体积%,更优选含量为0.2-0.5体积%;所述癸基甲基亚砜占组合物的含量为1-4体积%,优选含量为1-3体积%。更优选含量为1-1.5体积%;所述水占组合物的含量为3-8体积%,优选含量为3-5体积%,更优选3-4体积%。
本发明的一个实施例公开了一种治疗皮肤多种损伤创面的药物组合物及其重要组分,其中,所述药物组合物的重要组分由占组合物终体积比丙三醇80-90%,1,2丙二醇6-15%,水溶性月桂氮酮0.2-2%或癸基甲基亚砜1-4%,水3-8%构成。
本发明的一个具体实施例公开了一种治疗皮肤多种损伤创面的药物组合物的重要组分,单独治疗无菌创口创面,其中所述药物组合物的重要组分由占组合物终体积比为丙三醇83.5%、1,2丙二醇10%、水溶性月桂氮酮0.5%、水6%构成。
在一些具体的实例中,本发明所述的皮肤多种损伤创面治疗用的药物组合物的重要组分丙三醇优选是由医用分析纯丙三醇(Glycerol,甘油,密度1.236g/ml,500ml重628g,分子式C3H8O3,分子量92.09,纯度≥99%)、1,2丙二醇(1,2-Propanediol,分子式C3H8O2,分子量76.09,纯度≥99%)、水溶性月桂氮酮和水按特定配比组成,按终体积百分含量计算,其中丙三醇占80%-90%、1,2丙二醇占6-15%,这是充分利用这两个成分具有的液体形态和吸湿保湿的特性,吸收创面的渗液,同时又不致创面过于干燥。
本发明所述的用于皮肤多种损伤创面治疗的组合物中含有月桂氮酮(Laurocapram,分子式C18H35NO,分子量281.48,分析纯>98%,相对密度(20℃)0.906-0.926,酸碱度中性),其中,本品系油溶性氮酮改性成为水溶性氮酮,为癸基甲基亚砜同吡咯酮的复合体,无色透明粘稠液体。对亲水性药物活性成分有明显的透皮助渗作用,使皮肤角质层与脂质相互作用,降低了有效物质向角质层间隙中脂质相转移的温度,增加了流动性,使药物或活性添加剂在角质层中的扩散阻力减小,起到很强的促渗作用。
水溶性月桂氮酮能有效地增加组合物中所含药物的渗透吸收效果,从而达到不仅抑制杀灭创面表层而且能抑制杀灭创面深层的致病细菌,充分地发挥药物的疗效、减少药物的用量。在一些实施例中,所述水溶性月桂氮酮的优选含量为2-20ml/L,6-10ml/L更优,2-5ml/L最优。在一些具体实施例中,所述水溶性月桂氮酮优选为医药级的水溶性月桂氮酮。
在一些实施例中,因功效相似,也可用癸基甲基亚砜替换月桂氮酮,所述癸基甲基亚砜优选含量为10-40ml/L,10-30ml/L更优,10-15ml/L最优。在一些具体实施例中,所述癸基甲基亚砜优选为医药级的癸基甲基亚砜。
本发明所述的用于皮肤多种损伤创面处置治疗的药物组合物的重要组分中,水是天然的良好溶剂,含有水的作用是:一定比例的丙二醇和水的混合液能延缓某些药物的水解,增加其稳定性,从而延长组合物的有效期。此外,由于高浓度的丙三醇吸湿性很强,加入少量的水,能平衡一下其很强的吸湿性。丙三醇合水,在高温高压条件下能增强中药材的药用有效成分的溶解性。水的优选含量为30-80ml/L,30-50ml/L更优,30-40ml/L最优。
在具体使用中,本申请人发现,这种特定配比构成的药物组合物的重要组分与精选的配方中药材的药用有效成分组成的药物组合物涂在创面能很快地封闭创面并使创面结一层透明的痂,能有效地预防和治疗创面感染,消除创面水肿,使创面停止渗出,减轻患者的体质消耗,能抗自由基、能保护创面、能营养创面的生发细胞生发修复创面,使创面在痂下较快地愈合,一般如II度烧伤创面都很少留下瘢痕。
本发明药物组合物中,含有中药原料药:
本发明所述药物组合物还包括黄芪、当归、丹参、赤芍中的至少一种,所述黄芪、当归、丹参、赤芍中的至少一种药材的药用有效成分是在高温高压条件用丙三醇合水进行提取。
黄芪
黄芪含有多种化学有效成分,主要包括皂苷类、黄酮类、多糖类、氨基酸及微量元素等,具有补气升阳、生津养血、托毒排脓、敛疮生肌的功效。黄芪在组合物中的优选含量为10-30g/L,10-20g/L更优,10-15g/L最优。
当归
当归含有挥发油、当归内酯、阿魏酸、烟酸、琥珀酸、β-谷甾醇、胡萝卜苷、单糖、多糖、磷脂、多种氨基酸及无机元素等,具有补血活血、调经止痛、脱毒消肿、补虚化瘀、滋阴养血、润泽皮毛的作用。当归的优选含量为5-20g/L,5-10g/L更优,6-8g/L最优。
丹参
丹参含有丹参酮、丹参酚、黄芩苷等有效成分,具有抗氧化、抗菌、活血通经、祛瘀、凉血消痛、排脓止痛、长肉生肌、促进创面愈合的作用。丹参的优选含量为5-20g/L,5-15g/L更优,8-10g/L最优。
赤芍
赤芍含芍药苷、芍药碱、芍药醇、儿茶精、没食子酸乙酯、挥发油等,有抗心肌缺血、改善血液微循环、抑制血小板聚集抗血栓形成,并有镇痛解痉、护肝、抗炎抗菌作用,对金黄色葡萄球菌及铜绿假单胞菌、真菌、疱疹病毒、肠道病毒均有抑制作用。赤芍的优选含量为5-20g/L,5-15g/L更优,8-10g/L最优。
本发明中所述的药物组合物还可以包括黄连、黄芩、黄柏、栀子中的至少一种,所述黄连、黄芩、黄柏、栀子中的至少一种药材的药用有效成分是在高温高压条件用丙三醇合水进行提取。
黄连
黄连含有多种异喹啉生物碱、小檗碱。能清除内毒素、抗金黄色葡萄球菌、大肠杆菌、具有清热燥湿、泻火解毒的作用。对于烧伤、黄连煎剂外用,不仅能抗感染,还能减少渗出、促进结痂。黄连的优选含量为5-20g/L,5-10g/L更优,6-8g/L最优。
黄芩
黄芩主要含黄酮类化合物,如黄芩素、汉黄芩素、汉黄芩苷、并含有挥发油、氨基酸的糖类。黄芩抑菌能力强,对金黄色葡萄球菌、溶血性链球菌、大肠杆菌、铜绿假单胞菌有明显的抑制作用,还具有抗炎、抗氧化作用。黄芩的优选含量为5-20g/L,5-10g/L更优,6-8g/L最优。
黄柏
黄柏主要含小檗碱、黄柏碱、黄柏酮,黄柏内酯。中医说热毒疮黄柏良,对金黄色葡萄球菌、溶血性链球菌、大肠杆菌、铜绿假单胞菌霉菌有明显的抑制作用。黄柏的优选含量为5-20g/L,5-10g/L更优,6-8g/L最优。
栀子
栀子主要含环烯醚萜类栀子苷、藏红花素、芦丁等黄酮类,能泻火除烦、清热利湿、凉血解毒,外用消肿止痛,对金黄色葡萄球菌、溶血性链球菌有较强的抑菌作用。栀子的优选含量为5-20g/L,5-10g/L更优,6-8g/L最优。
本发明中所述的药物组合物还包括白蔹、四季青、白芨、甘草中的至少一种,所述白芨、白蔹、四季青、甘草中的至少一种药材的药用有效成分是在高温高压条件用丙三醇合水进行提取。
白蔹
白蔹主要成分有没食子酸、酒石酸、谷甾醇、大黄酚、粘液质,具有清热解毒、消肿生肌的作用。本品苦寒清泄、辛散消肿、敛疮生肌止痛,对金黄色葡萄球菌、铜绿假单胞菌、大肠杆菌有明显的抑制作用。白蔹民间俗称“见肿消”,单味药应用就有很强的抗感染作用。白蔹的优选含量为5-20g/L,6-15g/L更优,8-10g/L最优。
四季青
四季青主要成分原儿茶酸、原儿茶醛、缩合型鞣酸、黄酮类及挥发油。具有清热解毒、凉血止血、敛疮作用。四季青具有抗菌抗炎、增加冠状动脉血流量、抗心肌缺血、对烧伤创面有形成保护性痂膜、能预防感染、阻止渗出的功能,有吸附能力,有一定的通透性,具有不增加创面深度等优点。四季青的优选含量为5-20g/L,5-15g/L更优,8-10g/L最优。
白芨
白芨主要成分是联苄类、菲类及其衍生物、少量挥发油粘液质。具有收敛止血、消肿生肌的作用。用于治疗皮肤皲裂、水火烫伤,能吸收创面渗出物、保护创面,促进创口愈合。白芨的优选含量为5-20g/L,6-15g/L更优,8-10g/L最优。
甘草
甘草含有100多种黄酮类化合物、60多类三萜类化合物、18种氨基酸及多种生物碱等。具有肾上腺糖皮质激素样作用,具有抗炎、抗氧化、调节免疫及解毒作用,还具有抗病毒及抗菌、补脾益气、清热解毒、缓急止痛、调和诸药的功效。甘草的优选含量为5-15g/L,6-12g/L更优,8-10g/L最优。
本发明中所述的药物组合物还包括乳香、没药、血竭、儿茶中的至少一种,所述乳香、没药、血竭、儿茶中的至少一种药材的药用有效成分是用1,2丙二醇以浸泡法提取。
乳香
乳香主含树脂、树胶及挥发油。能镇痛消炎,具有活血行气止痛、消肿生肌的功效,是治疗疮疡痈疽疔毒的重要药物。乳香的优选含量为3-10g/L,5-8g/L更优,5-6g/L最优。
没药
没药主含挥发油、树脂、树胶。水浸剂对真菌有抑制作用,常与乳香配对,发挥活血止痛、消肿生肌、加强祛瘀的作用。中医认为瘀血不去、新血不生。没药的优选含量为3-10g/L,5-8g/L更优,5-6g/L最优。
血竭
血竭含有血竭素、血竭红素、树脂酸等。能止血活血、抗炎镇痛,具有活血化瘀、敛疮生肌的功效。血竭的优选含量为3-10g/L,5-8g/L更优,4-5g/L最优。
儿茶
儿茶含有儿茶酚,能抗氧化、抗菌(抑制革兰氏阳性菌和阴性菌、抑制金葡菌、肠球菌、大肠杆菌、抗流感病毒),具有活血疗伤、止血生肌、收湿敛疮的作用。儿茶的优选含量为3-10g/L,5-8g/L更优,4-5g/L最优。
本发明所述的药物组合物,其中,所述药物组合物还可以包括混溶入抗菌素。
本发明所述抗菌素包括庆大霉素、氯霉素。
本发明组合物除上述配方成分之外,对有些创面感染严重的病例,可根据创面感染的病原学诊断,在药敏试验的指导下,临时往每100ml组合物中加入一组抗菌素,如:8万单位庆大霉素和0.25克氯霉素(但不限于上述两种,也可选择其它适合的一组抗菌素),充分摇匀后涂用在创面上。
本发明的一个实施例公开了一种治疗皮肤多种损伤创面的药物组合物,其中,所述药物组合物是基本由下述终质量体积比的原料药黄芪10-30g/L、当归5-20g/L、丹参5-20g/L、赤芍5-20g/L、黄连5-20g/L、黄芩5-20g/L、黄柏5-20g/L、栀子5-20g/L、白蔹5-20g/L、四季青5-20g/L、白芨5-20g/L、甘草5-15g/L、乳香3-10g/L、没药3-10g/L、血竭3-10g/L、儿茶3-10g/L和终体积百分含量的丙三醇80-90%、1,2丙二醇6-15%、水溶性月桂氮酮0.2-2%或癸基甲基亚砜1-4%、水3-8%制成。
本发明的一个实施例公开了一种治疗皮肤多种损伤创面的药物组合物,其中,所述原料药的终质量体积比为黄芪10-20g/L、当归5-10g/L、丹参5-15g/L、赤芍5-15g/L、黄连5-10g/L、黄芩5-10g/L、黄柏5-10g/L、栀子5-10g/L、白蔹6-15g/L、四季青5-15g/L、白芨6-15g/L、甘草6-12g/L、乳香5-8g/L、没药5-8g/L、血竭5-8g/L、儿茶5-8g/L和终体积百分含量的丙三醇80-90%、1,2丙二醇6-15%、水溶性月桂氮酮0.6-1%或癸基甲基亚砜1-3%、水3-5%。
本发明的一个实施例公开了一种治疗皮肤多种损伤创面的药物组合物,其中,所述原料药的终质量体积比为黄芪10-15g/L、当归6-8g/L、丹参8-10g/L、赤芍8-10g/L、黄连6-8g/L、黄芩6-8g/L、黄柏8-10g/L、栀子6-8g/L、白蔹8-10g/L、四季青8-10g/L、白芨8-10g/L、甘草8-10g/L、乳香5-6g/L、没药5-6g/L、血竭4-5g/L、儿茶4-5g/L和终体积百分含量的丙三醇80-90%、1,2丙二醇6-15%、水溶性月桂氮酮0.2-0.5%或癸基甲基亚砜1-1.5%、水3-4%。
本发明的具体实施例公开了一种治疗皮肤多种损伤创面的药物组合物,其中,所述原料药的终质量体积比为黄芪20g/L、当归15g/L、丹参15g/L、赤芍15g/L、黄连10g/L、黄芩10g/L、黄柏10g/L、栀子10g/L、白蔹15g/L、四季青15g/L、白芨15g/L、甘草12g/L、乳香8g/L、没药8g/L、血竭6g/L、儿茶6g/L和终体积百分含量的丙三醇80%、1,2丙二醇14%、水溶性月桂氮酮1%、水5%。
本发明的具体实施例公开了一种治疗皮肤多种损伤创面的药物组合物,其中,所述原料药的终质量体积比为丹参20g/L、黄柏20g/L、四季青20g/L、白芨15g/L、甘草15g/L、儿茶8g/L和终体积百分含量的丙三醇88.4%、1,2丙二醇8%、水溶性月桂氮酮0.6%、水3%。
本发明的具体实施例公开了一种治疗皮肤多种损伤创面的药物组合物,其中,所述原料药的终质量体积比为黄芪10g/L、当归8g/L、丹参8g/L、赤芍8g/L、黄连6g/L、黄芩6g/L、黄柏6g/L、栀子6g/L、白蔹10g/L、四季青10g/L、白芨10g/L、甘草8g/L、乳香5g/L、没药5g/L、血竭4g/L、儿茶4g/L和终体积百分含量的丙三醇84.7%、1,2丙二醇12%、水溶性月桂氮酮0.3%、水4%。
本发明的另一方面公开了所述的药物组合物的制备方法,其中,所述制备方法的包括以下方法:精选称取适量黄芪、当归、丹参、赤芍、黄连、黄芩、黄柏、栀子、白蔹、四季青、白芨、甘草中至少三种,投入对应量丙三醇混合对应量的蒸馏水中,在水蒸汽0.02MPa气压和105℃温度的环境下,隔层加热含原料药的丙三醇10分钟,冷却后滤去药渣,损耗的丙三醇合水补足量;精选称取乳香、没药、血竭、儿茶的至少一种,投入到对应量的1,2丙二醇中,浸泡24小时后,滤去药渣,损耗的1,2丙二醇补足量;将含有原料药有效成分的丙三醇、含有原料药有效成分的1,2丙二醇与对应量的水溶性月桂氮酮或癸基甲基亚砜混合,充分搅匀,灌装灭菌。
本发明组合物中所含的中药材药用有效成分是以丙三醇或1,2丙二醇作为溶媒提取的。在常温下,中药材的药用有效成分在丙三醇中的溶解度低,且析出慢。本申请人发现,在丙三醇中加入少量的水,用适当的压力、温度,经过一定的时间,丙三醇对中药材的药用有效成分溶解度良好。丙三醇的沸点290℃。在实际操作中,用高压水蒸汽把丙三醇合水隔层加热至105℃,时间维持10分钟。选定这样的温度和时间,是为了既保持丙三醇的化学稳定性,又能理想地溶出所投入的中药材药用有效成分。
1,2丙二醇在组合物的共同组分中含量比例较低,但其使用量作为浸泡溶解提取组合物中的乳香、没药、血竭、儿茶的药用有效成分的溶媒是够用的。
本发明遵循中医外科学清热解毒、活血消肿、祛腐生肌、收湿敛疮的治则,以清通相辅,以通为补,补泻平衡,通补兼施的思想,将黄芪、当归、丹参、赤芍;黄连、黄芩、黄柏、栀子;白蔹、四季青、白芨、甘草;乳香、没药、血竭、儿茶,组成了一个新的药材品种多、剂量轻的由四个药阵构成的大处方,加入一个既吸湿、保湿、成膜,又作溶媒的基础药阵。五阵协力,理法周全,方药精当,创制了一个新的制剂,本发明人在临床实践中屡用屡效。
在处方结构方面,宏观上,第一药阵黄芪、当归、丹参、赤芍,补气补血,托里排毒,属君;第二药阵黄连、黄芩、黄柏、栀子,清毒泻火,属臣;第三药阵白蔹、四季青、白芨、甘草,收湿敛疮消肿,属佐;第四药阵乳香、没药、血竭、儿茶,行气活血通络,祛腐生肌,属使。微观上,四个药阵为四个小处方,每方四味中药,依其功能性状,按上述顺序,分别构成对应的君、臣、佐、使。
本发明还公开了所述的药物组合物的在制备用于治疗皮肤多种损伤创面的外用药物中的用途。
在一些实施例中,所述皮肤多种损伤创面不包括:因结核菌感染或恶性肿瘤引起的皮肤溃疡、因雄雌激素分泌失衡而发生的痤疮。
在一些具体实施例中,本发明所述皮肤多种损伤创面包括烧伤创面、烫伤创面、皮肤擦挫伤创面、切割后的缝合创口、褥疮创面、皮肤感染后的肉芽组织创面。
发明的有益效果
本发明的有益效果在于公开了一种用于人类皮肤多种损伤创面治疗的液态外用药物组合物。使用这种含有中药原药料药用有效成分的药物组合物,能快速有效地封闭创面,消除创面水肿,减少、停止创面的渗出,药物组合物与创面已有的渗出液结合形成透明薄痂,能保护创面基底及周围有生命力的细胞免受进一步的损伤,预防和控制创面感染,促进创面痂下愈合,最大限度地减少瘢痕的形成。该药物组合物有用于治疗皮肤多种损伤创面的外用药物的用途。
附图说明
图1示出的是本发明药物组合物制剂3制成品实样图。
具体实施方式
下面通过具体实施方式及实施例数据对本发明作进一步的说明。尽管为了清楚的目的,在下文中使用了专用术语,但这些术语并不意味着定义或限制本发明的范围。
如本文中所使用,术语“医用”指代纯度大于95%的试剂,在本发明中实施例中使用的“医用丙三醇”为分析纯级别的医用甘油,密度1.236g/ml,500ml重628g,分子式C3H8O3,分子量92.09,纯度≥99%;“医用1,2丙二醇”的纯度≥99%。
如本文中所使用,术语“医药级”指代化学品的纯度能够被用于人类药物。本发明中水溶性月桂氮酮是医药级的。
如本文中所使用,术语“治疗”是指逆转、减轻或抑制该术语所应用的疾病的进展,或疾病的一种或多种症状。如本文所使用的,根据患者的状况,该术语也包括预防疾病,包括预防疾病或与其相关的任何症状的发生,以及减轻病症或其在发生前的任何病状的严重性。
如本文中所使用,术语“丙三醇合水”是指按照特定配比将丙三醇和水进行混合得到的溶剂。在本发明实施例使用的“丙三醇合水”中丙三醇的体积为80-90份,水的体积为3-8份。本发明具体实施例使用的“丙三醇合水”中丙三醇和水的体积比为800:50或884:30或847:40或835:60。
以下通过具体实施例对本发明做进一步的详细描述,本领域技术人员根据本发明做出各种改变,均应属于本发明所附权利要求的范围。下述实施例中的实施方法,如无特殊说明,均为常规方法。
具体实施例:
实施例1药物组合物的制备
本发明组合物制剂1-3按表1配比量及下述工艺流程调制。
调制工艺流程如下:
1)精选中药材黄芪、当归、丹参、赤芍、黄连、黄芩、黄柏、栀子、白蔹、四季青、白芨、甘草,按表1中制剂的组成分量称取,投入表1中相同制剂对应量丙三醇混合对应量的蒸馏水(丙三醇合水)中,用水蒸汽0.02MPa气压,约105℃,隔层加热含中药材的丙三醇10分钟,冷却后滤去药渣,损耗的丙三醇合水补足量。
2)精选中药材乳香、没药、血竭、儿茶,按表1中制剂对应量称取,投入到表1中相同制剂对应量的1,2丙二醇中,浸泡24小时后溶解出药用有效成分,滤去药渣,损耗的1,2丙二醇补足量。
3)将含有中药汁的丙三醇合水、1,2丙二醇,加表1中相同制剂对应量的蒸馏水和水溶性月桂氮酮混合,充分搅匀,灌装灭菌即成。
制剂4的制备工艺仿照以上步骤,但没有称取中药材。
表1:组合物制成品量以1000ml计算
本发明组合物除上述配方成分之外,对有些创面感染严重的病例,可根据创面感染的病原学诊断,在药敏试验的指导下,临时往每100ml组合物中加入一组抗菌素,如:8万单位庆大霉素和0.25克氯霉素(但不限于上述两种,也可选择其它适合的一组抗菌素),充分摇匀后涂用在创面上。
实施例2药物组合物制剂4治疗皮肤切割后缝合创口的临床验证
表1中制剂4是本发明药物组合物的重要组成部分,由丙三醇、1,2丙二醇、水溶性月桂氮酮和水按特定配比组成。皮肤切割创口缝合后,传统的治疗法是用75%酒精纱布覆盖。下面是治疗皮肤切割后缝合创口,用本发明药物组合物制剂4与用传统酒精敷料的临床对比观察。
1)一般资料:
选择无菌手术病例共50人,年龄在20岁-60岁,其中,男性40人,女性10人,平均分成治疗组和对照组,皮肤切口长度均在8公分以上。
2)治疗方法:
a.治疗组:皮肤切口缝合清理消毒完毕后,用棉球将制剂4涂在缝合的创口针口上,1-2分钟后用消毒纱布覆盖创口缝合处,胶布固定。第2天更换创口敷料时,再涂制剂4一次,第7-8天拆线后及时涂制剂4封闭针口。
b.对照组:皮肤切口缝合清理消毒完毕,用75%酒精纱布敷在创口缝合处,再用消毒纱布覆盖,胶布固定。第3天更换创口处的敷料,有少量病例出现创口有感染的迹象,往后每天更换创口敷料,直至创口愈合。
3)疗效评定标准
在创口缝合3天始至7天后拆除缝线时,根据创口的愈合状态及缝合针口的炎性反应评定疗效。
a.愈合良好:3天后创口针口均有痂,无或很少渗出物,创口处的敷料污渍少,术后7天后,创口I期愈合,针口炎性反应小。
b.愈合较好:3天后,创口针口出现少量的渗出液,创口处的敷料有明显的污渍,涂碘酒,连续3天更换创口处的敷料,渗出物渐少,创口针口渐结痂,一般术后8-9天拆线,创口基本I期愈合,针口充血红润。
c.愈合不良:术后3天更换缝合处的敷料,创口有分泌物,敷料有些潮湿,针口发红,须间隔拆去缝线,以利创口分泌物引流,天天更换敷料,创口愈合期延长。
4)治疗结果(见表2)
表2本发明药物组合物制剂4与传统的75%酒精纱布治疗皮肤切割缝合后无菌创口治疗的临床对比观察结果统计
5)讨论
从表2临床对比观察结果统计说明,本发明药物组合物制剂4治疗皮肤切割创口缝合的疗效优于传统的以75%酒精纱布覆盖缝合创口的治疗方法,这是因为酒精虽能杀菌,但它是易挥发的杀菌剂,75%酒精纱布敷在缝合创口上,几个小时后,酒精挥发完,创面就只剩下纱布了。如果病人护理不周,细菌容易从纱布的边缘侵入到创口针口,进而引发不同程度的创口感染。而本发明药物组合物制剂4中的组分主要是丙三醇和1,2丙二醇,是不易挥发的,其与创口针口接触后,能快速完全地封闭创口针口,吸收创口针口少量的渗液,与渗液中的蛋白质结合形成一层透明的薄痂,严密地保护创面免受外来细菌的侵袭,因而能使创口针口清洁干燥,达到良好的愈合。
实施例3药物组合物治疗烧伤病人创面的临床观察
从皮肤多种损伤创面的病理生理愈合机制来看,烧伤所形成的皮肤损伤创面最严重、最复杂、最有代表性。本发明人以烧伤创面为模型说明所发明的药物组合物对皮肤损伤创面的治疗实例。
处置和治疗烧伤的原则应是早期预防和治疗休克,早期短程足量应用高效抗生素,早期科学地处置烧伤创面,使创面得到严密覆盖,减少创面渗出,就是减少病人体能消耗,保持创面干燥,并使广谱抗菌药达到创面深部,抗自由基、抗氧化、保护残存的上皮生发细胞不凋亡,促进创面尽早愈合,是对烧伤治疗的重要环节。
本发明的一种治疗皮肤多种损伤创面的药物组合物就是根据以上对创面治疗的原则要求设计的。组合物的重要组分也是基质,选择以浓丙三醇和1,2丙二醇为主,具有很强的吸湿性和适当的保湿性,与创面渗液中的水分和高于血浆含量的氨基酸结合形成干而不硬的透明痂,使创面快速得以封闭,涂药后空气中落入创面的细菌不能生长,细菌不能从外部入侵,同时因配比中有适当含量的月桂氮酮或癸基甲基亚砜,可带领配方中的抗菌抑菌、营养、抗氧化、改善微循环的药物有效成分渗透到创面的深部,从而改善创面组织的血液供应,阻灭肠道通过血液循环到达创面的细菌,减轻创面早期的炎症再损伤,起到“内外兼修”的理想治疗效果,这是本发明者在本发明实践中的欣喜发现。相信这将为烧伤创面修复科学新的探索起到抛砖引玉的作用。
本发明者在长期的临床医疗实践中,自配自用本发明药物组合物治疗了大量的皮肤多种损伤创面的患者,涉及门诊和病房的一般外科换药、急诊皮肤擦挫伤的处置治疗、烧烫伤创面的用药、长期卧床的褥疮治疗等近千例,全部取得了明显优于传统的创面用药的疗效,既促进了创面的愈合、缩短了创面的疗程、减少了病人的痛苦、节省了医疗费用,又减轻了医务人员的劳动。本发明药物组合物的组成成分的来源,均是公知的记载在中国药典上的平常药品,但经本发明人在实践中依中西医结合外科的医理药理组方配比,用特定的方法提取药用有效成分,赋予新颖的剂型,使中西医结合治疗皮肤多种损伤创面的绩效大放光彩。
本发明药物组合物制剂3治疗烧伤病人创面58例临床观察
1)一般资料:
门诊治疗患者31例,为烧伤面积均小于体表面积10%的轻型烧伤患者。
住院治疗患者27例,为烧伤面积占体表面积10%-30%的患者。
按性别分,男性37例,女性21例。
按年龄分,2-14岁12例,15岁以上46例。
按烧伤深度分,浅II度43例,深II度11例,III度或相当于III度4例。
2)诊断标准:
浅II度烧伤,伤处皮肤起水疱,水疱剪开后创面鲜红,感觉剧痛。
深II度烧伤,伤处皮肤有水疱或有透明干痂,疱内或痂下创面红白相间,痛觉较轻。
III度烧伤,伤处皮肤呈半透明的褐色焦痂,创面痛觉消失,或由II度烧伤创面发生感染造成皮肤全层缺失所致。
3)治疗方法:
对于II度烧伤,伤后当日剪破水疱,排除渗液,使用本发明药物组合物制剂3,在水疱皮上涂药;伤后过24小时后,揭除水疱皮,在烧伤创面上涂药,对于小面积III度烧伤,待肉芽组织长到与周围组织相平后,在肉芽组织上涂药,均采用暴露方法。
4)疗效评定标准:
涂药时间3-5天后观察创面的发展变化。浅II度烧伤创面观察8天,可根据干痂与创面结合的状况,判断创面的愈合趋势;深II度烧伤创面涂药观察20天,可根据痂下有无积脓,判断创面的愈合趋势;已经严重感染的II度烧伤或小面积的III度烧伤,在不断清除坏死组织,创面肉芽组织长平后,多次涂药,共观察30天,可根据创面结痂和创面周边状况,判断创面的愈合趋势。少数不能确定愈合趋势的病例,则以最终治疗结果判定。
显效:浅II度烧伤在2周内创面愈合脱痂,深II度烧伤创面在4周内愈合脱痂,小面积III度烧伤的创面干燥、痂下无波动、肉芽创面感染得到有效控制。
好转:创面有少部分发生感染,涂药时间超过5天,创面愈合时间延长。
无效:达不到以上好转的标准。创面转由植皮愈合。
5)治疗效果(见表3):
表3本发明药物组合物制剂3对58例烧伤病人创面治疗结果的统计
总有效率98.3%
实施例4长期临床实践中皮肤多种损伤创面的治疗病案
实例一类,使用本发明药物组合物制剂3
对于浅II度或深II度烧烫伤的创面,剪去水疱,以消毒棉球浸泡组合物药液,在创面上轻轻涂擦,药液厚1毫米即可,涂药后创面暴露,不用敷料,创面会在4-6个小时内形成透明薄痂。如果创面渗出液较多,6小时后再涂药一次,第一天最多涂药三次。第二天如发现痂下创面清洁、透明痂干燥,只要在透明痂上再加涂一次药液即可。如发现透明痂下有坏死组织,可用生理盐水棉球润化透明痂,清除坏死组织,再涂组合物。第三天,透明痂干净、痂下创面清洁、继续暴露创面,只在创面上涂一次药即可。如发现痂下还有坏死组织,继续清除再涂药。
以上治疗浅II度和深II度烧烫伤,只要就诊及时,绝大多数创面不会发生感染,能如期愈合。
如果烧烫伤损坏皮肤全层,甚至伤及皮下组织,则按III度烧伤治疗原则处理。在肉芽组织长到与周边正常皮肤相平后,如创面不大,不用植皮,只涂本组合物药液,创面肉芽组织能很快结透明痂,创面水肿消退,会在痂下逐渐愈合。因创面愈合快,肉芽组织没有反复增生,所以涂治本发明组合物药液后肉芽创面愈合的瘢痕也较平软。
1)
徐X,女,2岁,家住城镇,1994年5月21日就诊,诉其母从厨房端一大碗刚出锅的炖肉往餐桌边走,2岁女孩徐X绕膝叫妈,撞上其母的腿脚,高温肉汤溢出淋在女儿头上,烫伤患儿头面部,急诊就医。检查见患儿左耳、左前额、左面颊部红肿起水疱,左眼睁不开。诊断:左侧面部II度烫伤,受伤面积占体表面积约2%。治疗:剪去水疱,在水疱皮上涂本发明组合物药液,当日涂二次。第2日,剪去水疱皮,在创面上继续涂药。第3天创面全部被透明痂覆盖保护,无渗出,无分泌物。第4日创面干燥,无感染,停止涂药。第5日,左头面部及左耳渐消肿,用棉签轻触不疼痛。第10日,创面保护痂部分开始脱落,显示烫伤创面一期愈合。半年后随访,面部和左耳伤后未留瘢痕。
耳朵两层皮肤包着一层软骨,表面不平,以往烫伤后,用药不好包扎,容易感染,感染后治疗很困难。用本发明组合物涂在II度烧烫伤的耳朵上,能使耳朵上的受伤创面被药物全覆盖,不用包扎,能很快地形成保护痂,有效地抗感染、愈合快。面部II度烧烫伤一感染就可能成为III度烧烫伤,愈合后会形成不同程度的瘢痕,造成损容。面颈部II度烧烫伤,只要在伤后早期用本发明组合物药液正确地治疗,不会发生感染,不会形成瘢痕。
2)
於X,男,3岁,家住城镇。1995年7月6日就诊,诉在家玩耍扳倒桌上的开水瓶,烫伤颈、胸、腹部及会阴部和双下肢的部分皮肤,伤后约2小时来院就医,伤部多处起大水疱,阴茎及阴囊也有水疱。诊断:身前部分皮肤II度烫伤,受伤面积占体表面积约10%。治疗:除全身补液等治疗外,受伤创面用本发明组合物药液涂治,涂药厚约1mm,创面全程暴露。第1日,剪破水疱皮,将药液涂在水疱皮上,日涂3次。第2日,揭去水疱皮,将药液涂在创面上,日涂3次。第3日,创面已形成透明保护痂,部分痂下可见鲜红的毛细血管,未发现痂下有坏死组织,继续在痂面上涂药1次。第4日,创面干燥,用棉签探触无分泌物,无明显疼痛,创面停止用药,嘱加强营养。第8日,患儿精神良好,饮食正常,创面带痂出院,嘱一周后来院复诊,创面痂覆盖良好,干燥无触痛。又过一周再来复诊,见痂皮渐脱落,创面红嫩平整,外生殖器形态正常。
会阴部创面难包扎,容易感染。用本发明药物组合物,暴露疗法效果好。
3)
梅XX,男,38岁,农民。1996年7月25日就诊,诉昨深夜开小拖拉机在田间作业,突发机械故障熄火。就地自己维修时,柴油喷雾洒在高温的发动机气缸上,瞬间火光一闪,火焰烧伤患者的头、面、颈部。今天一早来就诊,患者头面颈部散落油污,双耳、头发、前额、面部肿胀,面目全非,检查双眼角膜及呼吸道未损伤。诊断:头面颈部II度烧伤,受伤面积占体表面积约8%。治疗:除全身输液预防感染治疗外,局部用干棉签轻拭油污后,第1日在受伤部位涂本发明组合物药液,日涂3次。第2日,尽量揭去一层水疱皮,在创面上涂本发明组合物药液,日涂3次。第3日,大部分创面被痂覆盖保护,干燥,只有发际和耳廓尚有少数小水疱未消除未吸收,继续清创后涂组合物药液。至第5日,整个创面痂下无积液,肿胀有所消退。至第8日,创面被痂下保护得好,涂药停止。至第14日,痂皮干燥,周围组织消肿,无明显触痛。又过两周,痂皮有松动,部分可剥脱,创面愈合良好。半年后随访,未发生瘢痕损容。
4)
伍XX,女,6岁,家住农村。1997年9月18日就诊,诉40多天前在家被绊倒,一屁股坐在刚从灶台移至地面的粥锅里,烫伤整个臀部及双大腿后侧部分皮肤,在当地卫生院治疗一天后转往武汉同济医院治疗40天,大部分创面愈合,仍剩下右侧臀部一大块创面,需天天交换敷料。患儿父亲讲,患儿这个大创面在同济医院天天交换敷料不见创面缩小,医院拟采取再次手术,家长经济耗尽,负担不起,遂要求出院回本地医院诊治。患儿来我处就诊时,面容痛苦、全身营养状况差、清瘦、轻度贫血貌,右侧臀部正中有一8×10cm的创面,创面上肉芽组织水肿略高出周围皮肤。这些症状表现,是因为患儿烫伤一个多月,皮肤存在较大的创面、渗出,天天丢失血浆蛋白和其它营养物质,对身体消耗很大。身体蛋白质偏低,创面愈合就会困难。首先要封闭创面,避免身体继续丢失蛋白质等营养物质。给予本发明药物组合物100ml,用棉签蘸组合物给患儿创面涂药示范1次,嘱患儿父亲将上述组合物药液和棉签带回家后涂用,每日涂2次,暴露创面,连用5日;第6日来复诊,发现原来水肿的肉芽组织收缩了,与周围组织平了,创面上覆盖了一层干痂,痂下无液化物,嘱可停止涂药,避免挤压创面处。再过10天来复诊,创面还是被干痂覆盖,
痂下创面进一步好转;又过2周,创面上的痂皮逐渐脱落,痂下创面形成较软的瘢痕愈合。
5)
张XX,女,17岁,地区卫校学生。1998年7月12日就诊,诉半个月前在校穿短裤从学生食堂提着开水瓶回宿舍,不料瓶塞脱落,开水流出,烫伤患者右大腿外侧中部至外踝处皮肤,伤后每日到校医务室治疗。两周后放假回家,来我处就诊。检查:患者右大腿外侧中部以下至小腿外侧有一条感染创面,深达皮下组织,创面有多处黄绿色脓性坏死组织,不易拭掉,诊断为II度烫伤并感染。治疗:在尽量消除创面坏死组织后,用加入庆大霉素、氯霉素的本发明药物组合物涂在创面上。第1日每6小时涂1次,第2日涂2次,第3日涂2次,第4日来复诊,患者告诉创面局部疼痛明显减轻,检查见创面大部分干燥,仍有少量的痂下积脓,以生理盐水棉球润洗去局部有脓的干痂后,清理痂下的脓液及坏死组织,继续涂上述药液。这样又连续3天治疗后,患者的创面渐消肿,被干痂覆盖,痂下创面清洁,无痂下积脓。嘱停止涂药,避免压碰搔抓创面上的痂皮,静待结痂自行脱落。
实例二类 使用本发明药物组合物制剂2
对于皮肤擦挫伤,手术切口缝合后的皮肤创口,在清洁拭干创口后,涂擦本发明组合物药液。皮肤擦挫伤的创面涂药后暴露,一般不用敷料。如果用一层薄薄的消毒纱布也只是为了将创口与衣物隔开。
皮肤擦挫伤或切割后的缝合创口,或缝合伤口拆去缝线时,经涂本发明组合物药液后,能预防外面的细菌入侵伤口感染。
1)
余XX,男,34岁,教师。1998年8月26日就诊,诉骑摩托车转弯时摔在水泥路面上,擦伤右半侧身体,急诊来院。检查:患者右半身从脸、手、肘、腰腹部及大小腿外侧广泛皮肤擦伤,部分伤口血肉模糊,全身未见骨折,胸腹未见脏器损伤。诊断:右半身皮肤软组织广泛擦挫伤。治疗:继续观察全身内脏及骨骼是否有伤,注射破伤风抗毒素,清理皮肤创面后,在创面上涂本发明组合物药液。第1日涂3次。第2天创面全部结痂,疼痛有所缓解,再在痂上涂药2次。第3天,创伤处疼痛明显减轻,创面干燥,轻触摸不痛。停止涂药,静养10日后,创面全部愈合。
2)
王XX,男,41岁,职员。2002年9月2日就诊,诉昨晚淋浴时,浴室钢化玻璃门突发爆裂,碎玻璃渣扎伤患者右半身鲜血直流,经当地外科急诊包扎等处理后,今天来我处就诊,拆除包扎的敷料,在伤口上涂用本发明组合物。第1日涂2次。第2次伤口完全被干痂覆盖保护,再在干痂上涂1次药。第3日轻触伤口不痛。停止用药,伤口一期愈合。
3)
李XX,男,68岁,退休职员。2005年8月21日就诊,诉昨晚起夜如厕撞在塑料水桶边上,伤及右小腿前面的皮肤,今天就诊,见右小腿胫骨前皮肤掀起一块约1×1.5cm大小的皮瓣,皮瓣蜷缩发紫。治疗:预防注射TAT,常规清创后,在创面涂本发明组合物。第1天涂2次。第2、第3日每天各涂1次。第4天创面已结与周围皮肤相平的干痂,创面边缘无肿胀,轻触不痛,嘱停止用药,避免碰撞创伤处。15日后,痂皮松动,18日后痂皮脱落,创面基本长平,无瘢,留下浅灰色色素沉着。18个月后随访,创面色素消退,伤处无痕。
实例三类 使用本发明药物组合物制剂1
对于皮肤感染性疾病,如脓疱疮、黄水疮、下肢溃疡、疖痈破溃后的肉芽组织创面,用生理盐水棉球对疮面或肉芽组织创面洗净拭干,涂擦本发明组合物药液,疮创面的感染能迅速得到控制而痊愈。
1)
朱XX,男,5岁,家住农村。1996年9月6日就诊,诉头部长脓疱疮10天,在家用金霉素软膏涂在疮上,未能控制疮流黄水。今来我处就诊时,检查:头发已剪短,发际脓痂与短发粘混在一起,以左侧为重,右侧面额部也有脓痂,体温37.1℃,全身状态尚好。治疗:以生理盐水洗去头面部的脓痂,重新剪除稍长的头发,用消毒纱布拭干疮创面后,用本发明组合物(100ml加入氯霉素0.25克),带药回家。第1日涂3次。第2日涂2次。第3天复诊,头面部脓疱疮创面全部结痂,没有黄水再流,感染得到控制,嘱继续涂两次药后,可停药观察。再过3天复诊,疮创面痂皮覆盖良好,基底周围无炎性肿胀,探触不痛。疮创面渐完全愈合。
2)
张XX,女,83岁,城镇居民。2002年11月2日就诊,诉在家摔倒,造成左侧股骨颈骨折,经骨外科固定手术后进ICU病房,卧床一周后出现骶骨部位褥疮,经常规褥疮护理换药未能控制褥疮的感染。改用本发明药物组合物,清洗拭干褥疮创面后涂药暴露创面。第1日涂药3次。第2日褥疮创面就结痂,无分泌物。继续每日涂药2次,连用5日,褥疮创面一直保持有痂覆盖,干燥,被褥擦掉干痂后就及时补涂组合物药液,创面血运好转,面积日渐缩小。2周后创面渐趋愈合。
3)
孙XX,男,56岁,农民。1998年9月11就诊,诉4日前开始,左上背部疼痛,逐日加重。起病第5日疼痛难忍,来院就医。检查:体温38.2℃,右上背部红、肿、热、硬结,中心皮下可见有黄色脓点,触痛明显,未破溃,局部无波动感。诊断:左上背部蜂窝织炎(背痈)。治疗:全身用四环素0.5,6小时1次口服,连用3天。局部在局麻下做“艹”形切开,打通脓腔,减压引流,以本发明组合物药液浸消毒纱布条放在切口内做引流条,每日换药1次。第2日,局部疼痛明显减轻,体温37.3℃。至第4日,体温36.8℃,局部不触不痛,肿胀明显消退,切口引流出分泌物量少。至第7日,切口内无脓性分泌物,无需再引流,改用压迫包扎两天后,切口长平,暴露创面,涂组合物药液,每日2次,共涂2日,创面形成保护干痂,痂下切口创面渐愈合。
以上,基于本发明的实施方式进行了说明,但本发明不限定于此,本领域的技术人员应该明白,在本发明的主旨的范围内能够以进行变形和变更的方式实施,这样的变形和变更的方式,理应属于本发明的保护范围。
Claims (10)
1.一种组合物,其中,所述组合物由丙三醇、1,2丙二醇、水溶性月桂氮酮或癸基甲基亚砜、以及水按特定配比组成,其中所述丙三醇占组合物的含量为80-90体积%,
其中,优选所述1,2丙二醇占组合物的含量为6-15体积%;优选所述水溶性月桂氮酮占组合物的含量为0.2-2体积%,优选含量为0.6-1体积%,更优选含量为0.2-0.5体积%;优选所述癸基甲基亚砜占组合物的含量为1-4体积%,优选含量为1-3体积%,更优选含量为1-1.5体积%;优选所述水占组合物的含量为3-8体积%,优选含量为3-5体积%,更优选3-4体积%。
2.如权利要求1所述的组合物在制备用于治疗皮肤多种损伤创面的药物中的用途。
3.如权利要求2所述的用途,其中所述药物包括中药材,所述中药材选自由黄芪、当归、丹参、赤芍中的至少一种;黄连、黄芩、黄柏、栀子中至少一种;白蔹、四季青、白芨、甘草中至少一种;和乳香、没药、血竭、儿茶中至少一种组成的组。
4.一种治疗皮肤多种损伤创面的药物组合物,其中,所述药物组合物包括丙三醇、1,2丙二醇、水溶性月桂氮酮或癸基甲基亚砜、以及水,其中所述丙三醇占组合物的含量为80-90体积%,其中,优选所述1,2丙二醇占组合物的含量为6-15体积%;优选所述水溶性月桂氮酮占组合物的含量为0.2-2体积%,优选含量为0.6-1体积%,更优选含量为0.2-0.5体积%;优选所述癸基甲基亚砜占组合物的含量为1-4体积%,优选含量为1-3体积%,更优选含量为1-1.5体积%;优选所述水占组合物的含量为3-8体积%,优选含量为3-5体积%,更优选3-4体积%。
5.如权利要求4所述的药物组合物,其中,所述药物组合物还包括中药材,所述中药材选自由黄芪、当归、丹参、赤芍中的至少一种;黄连、黄芩、黄柏、栀子中至少一种;白蔹、四季青、白芨、甘草中至少一种;和乳香、没药、血竭、儿茶中至少一种组成的组。
6.如权利要求5所述的药物组合物,其中所述黄芪、当归、丹参、赤芍、黄连、黄芩、黄柏、栀子、白蔹、四季青、白芨、甘草中的至少一种药材的药用有效成分是在高温高压条件用丙三醇合水进行提取;优选所述乳香、没药、血竭、儿茶中的至少一种药材的药用有效成分是用1,2丙二醇以浸泡法提取。
7.如权利要求5所述的药物组合物,其中,
所述黄芪占组合物的含量为10-30g/L,优选含量为10-20g/L,更优选含量为10-15g/L;
所述当归占组合物的含量为5-20g/L,优选含量为5-10g/L,更优选含量为6-8g/L;
所述丹参占组合物的含量为5-20g/L,优选含量为5-15g/L,更优选含量为8-10g/L;
所述赤芍占组合物的含量为5-20g/L,优选含量5-15g/L,更优选含量为8-10g/L;
所述的黄连占组合物的含量为5-20g/L,优选含量为5-10g/L,更优选含量为6-8g/L;
所述的黄芩占组合物的含量为5-20g/L,优选含量为5-10g/L,更优选含量为6-8g/L;
所述的黄柏占组合物的含量为5-20g/L,优选含量为5-10g/L,更优选含量为6-8g/L;
所述的栀子占组合物的含量为5-20g/L,优选含量为5-10g/L,更优选含量为6-8g/L;
所述的白蔹占组合物的含量为5-20g/L,优选含量为6-15g/L,更优选含量为8-10g/L;
所述的四季青占组合物的含量为5-20g/L,优选含量为5-15g/L,更优选含量为8-10g/L;
所述的白芨占组合物的含量为5-20g/L,优选含量为6-15g/L,更优选含量为8-10g/L;
所述的甘草占组合物的含量为5-15g/L,优选含量为6-12g/L,更优选含量为8-10g/L;
所述的乳香占组合物的含量为3-10g/L,优选含量为5-8g/L,更优选含量为5-6g/L;
所述的没药占组合物的含量为3-10g/L,优选含量为5-8g/L,更优选含量为5-6g/L;
所述的血竭占组合物的含量为3-10g/L,优选含量为5-8g/L,更优选含量为4-5g/L;
所述的儿茶占组合物的含量为3-10g/L,优选含量为5-8g/L,更优选含量为4-5g/L。
8.如权利要求5所述的药物组合物,其中,所述药物组合物还可以包括混溶入的抗菌素,优选所述抗菌素包括庆大霉素、氯霉素。
9.如权利要求2或3所述的用途,其中所述皮肤多种损伤创面不包括:因结核菌感染或恶性肿瘤引起的皮肤溃疡、因雄雌激素分泌失衡而发生的痤疮,所述皮肤多种损伤创面包括烧伤创面、烫伤创面、皮肤擦挫伤创面、切割后的缝合创口、褥疮创面、皮肤感染后的肉芽组织创面。
10.如权利要求4-8任一项所述的药物组合物的在制备用于治疗皮肤多种损伤创面的外用药物中的用途,其中,所述皮肤多种损伤创面不包括:因结核菌感染或恶性肿瘤引起的皮肤溃疡、因雄雌激素分泌失衡而发生的痤疮;所述皮肤多种损伤创面包括烧伤创面、烫伤创面、皮肤擦挫伤创面、切割后的缝合创口、褥疮创面、皮肤感染后的肉芽组织创面。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110817611.5A CN113413375A (zh) | 2016-05-30 | 2016-05-30 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110817611.5A CN113413375A (zh) | 2016-05-30 | 2016-05-30 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
CN201610369784.4A CN105833279B (zh) | 2016-05-30 | 2016-05-30 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610369784.4A Division CN105833279B (zh) | 2016-05-30 | 2016-05-30 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113413375A true CN113413375A (zh) | 2021-09-21 |
Family
ID=56594972
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610369784.4A Active CN105833279B (zh) | 2016-05-30 | 2016-05-30 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
CN202110817611.5A Pending CN113413375A (zh) | 2016-05-30 | 2016-05-30 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610369784.4A Active CN105833279B (zh) | 2016-05-30 | 2016-05-30 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US10864240B2 (zh) |
EP (1) | EP3466447B1 (zh) |
JP (1) | JP6681482B2 (zh) |
CN (2) | CN105833279B (zh) |
WO (1) | WO2017206758A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105833279B (zh) | 2016-05-30 | 2021-06-22 | 傅远桥 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
CN106729444A (zh) * | 2017-02-17 | 2017-05-31 | 扬州大学 | 一种修复皮肤创面的凝胶乳及其制备方法 |
CN108403908A (zh) * | 2018-04-20 | 2018-08-17 | 江西金思康药业有限公司 | 一种亲肤性的创面愈合敷料及其制备方法 |
CN110339389A (zh) * | 2019-07-08 | 2019-10-18 | 生升美高科技(武汉)有限责任公司 | 一种油性创面敷贴及其制备方法 |
CN112439008A (zh) * | 2019-08-30 | 2021-03-05 | 鲁南制药集团股份有限公司 | 茵栀黄制剂的医药用途 |
CN112656839A (zh) * | 2020-12-31 | 2021-04-16 | 茂名市人民医院 | 烧伤膏药 |
CN113197844A (zh) * | 2021-05-07 | 2021-08-03 | 何胜男 | 一种无痕生肌膏 |
CN115957255A (zh) * | 2021-10-11 | 2023-04-14 | 陈小平 | 治疗皮肤溃烂,口鼻腔炎症的外用中药 |
CN114225091B (zh) * | 2021-11-18 | 2022-12-02 | 朗姿赛尔生物科技(广州)有限公司 | 一种生物酶伤口创面敷料及其制备方法 |
CN114504567B (zh) * | 2022-03-01 | 2023-10-20 | 云南云河药业股份有限公司 | 一种龙血竭液体创口贴及其制备方法 |
CN115531489A (zh) * | 2022-08-27 | 2022-12-30 | 浙江金圳健康科技有限公司 | 一种祛疤中药组合物及其制备方法 |
CN116650466A (zh) * | 2023-07-11 | 2023-08-29 | 李天才 | 一种具有清血热效果的解毒制剂及其制备方法与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0165696A2 (en) * | 1984-05-10 | 1985-12-27 | American Home Products Corporation | Improved transdermal dosage form |
CN1116539A (zh) * | 1995-04-24 | 1996-02-14 | 刘景文 | 烧烫灵膏 |
CN101874809A (zh) * | 2009-04-30 | 2010-11-03 | 宫家君 | 一种使用甘油dmso混合溶剂的局部抗炎外用药物组合物 |
CN102961479A (zh) * | 2012-12-14 | 2013-03-13 | 重庆市科学技术研究院 | 一种用于促进皮肤创面愈合的涂膜剂及其制备方法 |
CN104984383A (zh) * | 2015-06-26 | 2015-10-21 | 中国人民解放军第二军医大学 | 一种治疗烧伤创面的新型水凝胶敷料及其制备方法 |
CN105833279A (zh) * | 2016-05-30 | 2016-08-10 | 傅远桥 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1110365B (de) * | 1956-11-17 | 1961-07-06 | Assur Gjessing Oppegaard | Wundenkompresse |
US4855294A (en) * | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
US6964783B1 (en) * | 1999-06-08 | 2005-11-15 | Naturveda | Non-solid composition for local application |
JP4677192B2 (ja) * | 2004-02-20 | 2011-04-27 | 株式会社オゾテック | オゾン溶存グリセリン溶液の製造方法 |
CN1795897A (zh) * | 2004-12-30 | 2006-07-05 | 黄衍民 | 一种治疗消化道癌症和晚期癌痛的中药制剂 |
EP2051697A2 (en) * | 2006-07-05 | 2009-04-29 | Foamix Ltd. | Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof |
CN101583369B (zh) * | 2006-11-15 | 2015-03-11 | 关节炎缓痛补充剂有限公司 | 局部制剂及其用途 |
US20090062244A1 (en) * | 2007-09-04 | 2009-03-05 | Joseph Schwarz | Pharmaceutical composition |
US8513225B2 (en) * | 2008-10-03 | 2013-08-20 | Winlind Skincare, Llc | Composition and method for topical treatment of skin lesions |
JP2010195706A (ja) * | 2009-02-24 | 2010-09-09 | Kimio Katsuta | 新規殺菌・抗カビ・保湿性組成物 |
RU2586302C2 (ru) * | 2009-03-27 | 2016-06-10 | Молеак Пте. Лтд. | Терапия для стимуляции роста клеток |
CA2768947C (en) * | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US10029013B2 (en) * | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
CN101773511B (zh) * | 2010-02-05 | 2013-05-15 | 吴燕 | 治疗痤疮的复方外用组合药物及其制备方法 |
KR20110102811A (ko) * | 2010-03-11 | 2011-09-19 | 이상철 | 상처치료용 조성물 |
US20110230816A1 (en) * | 2010-03-18 | 2011-09-22 | Tyco Healthcare Group Lp | Gels for Transdermal Delivery |
CN102670690A (zh) * | 2011-03-14 | 2012-09-19 | 苏州博创园生物医药科技有限公司 | 一种抗牛皮癣纯天然药物乳膏及其制备方法 |
CN102178809B (zh) * | 2011-04-26 | 2012-11-14 | 王祥国 | 一种清热解毒消肿和活血止疼生肌的皮肤外用药物及其加工成药剂的方法 |
US20140120190A1 (en) * | 2012-10-20 | 2014-05-01 | Dong-Qing WEI | Methods of preparing prickly-ash peel extracts and cosmetic compositions incorporating prickly-ash peel extracts |
US10016486B1 (en) * | 2013-06-28 | 2018-07-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions using AMPK activators for pharmacological prevention of chronic pain |
CN103622886B (zh) * | 2013-09-13 | 2016-04-13 | 马应龙药业集团股份有限公司 | 具有祛痘功效的护肤组合物、制剂及其制备方法 |
CN103877388B (zh) * | 2014-04-16 | 2016-05-11 | 山东省立医院 | 一种治疗烧烫伤的药膏 |
JP2017529334A (ja) * | 2014-08-27 | 2017-10-05 | アッヴィ・インコーポレイテッド | 局所製剤 |
CN105411998B (zh) * | 2014-09-10 | 2019-07-02 | 天津法莫西医药科技有限公司 | 含有五味子乙素的治疗烧烫伤的外用组合物 |
WO2016077386A1 (en) * | 2014-11-10 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Topical sodium nitrite formulation |
CN105126087A (zh) * | 2015-09-23 | 2015-12-09 | 福建龙生生物科技有限公司 | 皮肤创伤修复外用溶液制剂及其制备方法和应用 |
CN105560331A (zh) * | 2015-12-30 | 2016-05-11 | 西安医学院 | 一种用于抗皮炎湿疹的药物及其制备方法和应用 |
-
2016
- 2016-05-30 CN CN201610369784.4A patent/CN105833279B/zh active Active
- 2016-05-30 CN CN202110817611.5A patent/CN113413375A/zh active Pending
-
2017
- 2017-05-23 EP EP17805703.0A patent/EP3466447B1/en active Active
- 2017-05-23 JP JP2018563615A patent/JP6681482B2/ja active Active
- 2017-05-23 WO PCT/CN2017/085443 patent/WO2017206758A1/zh active Search and Examination
-
2018
- 2018-11-29 US US16/204,352 patent/US10864240B2/en active Active
-
2020
- 2020-11-24 US US17/102,529 patent/US11571452B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0165696A2 (en) * | 1984-05-10 | 1985-12-27 | American Home Products Corporation | Improved transdermal dosage form |
CN1116539A (zh) * | 1995-04-24 | 1996-02-14 | 刘景文 | 烧烫灵膏 |
CN101874809A (zh) * | 2009-04-30 | 2010-11-03 | 宫家君 | 一种使用甘油dmso混合溶剂的局部抗炎外用药物组合物 |
CN102961479A (zh) * | 2012-12-14 | 2013-03-13 | 重庆市科学技术研究院 | 一种用于促进皮肤创面愈合的涂膜剂及其制备方法 |
CN104984383A (zh) * | 2015-06-26 | 2015-10-21 | 中国人民解放军第二军医大学 | 一种治疗烧伤创面的新型水凝胶敷料及其制备方法 |
CN105833279A (zh) * | 2016-05-30 | 2016-08-10 | 傅远桥 | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 |
Non-Patent Citations (3)
Title |
---|
周玉秋,等: ""中药外用佐治烧伤残余创面的护理进展"", 《护理学杂志》, vol. 25, no. 22, pages 92 - 95 * |
陈晓东,等: ""中药减压提取的实验方法"", 《机电信息》, vol. 1965, no. 17, pages 1411 - 31 * |
骆校权: ""丹参酮ⅡA透皮吸收在体评价技术研究"", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, vol. 2008, no. 01, pages 057 - 25 * |
Also Published As
Publication number | Publication date |
---|---|
JP2019517533A (ja) | 2019-06-24 |
US11571452B2 (en) | 2023-02-07 |
US20190125815A1 (en) | 2019-05-02 |
CN105833279A (zh) | 2016-08-10 |
EP3466447A4 (en) | 2020-03-18 |
CN105833279B (zh) | 2021-06-22 |
EP3466447A1 (en) | 2019-04-10 |
JP6681482B2 (ja) | 2020-04-15 |
US20210106638A1 (en) | 2021-04-15 |
EP3466447B1 (en) | 2024-08-21 |
US10864240B2 (en) | 2020-12-15 |
WO2017206758A1 (zh) | 2017-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105833279B (zh) | 皮肤多种损伤创面治疗的外用药物组合物及其制备方法 | |
US6027728A (en) | Herbal skin regeneration composition and method | |
CN101167847B (zh) | 一种有效治疗皮肤病的中药白酒制剂 | |
CN102091203A (zh) | 一种治疗难愈性创面的外用中药制剂及其制备方法 | |
CN104208245B (zh) | 手足癣中药药浴及制备方法 | |
CN106474350A (zh) | 一种植物抗菌素复方喷剂及其制备方法 | |
CN105943666B (zh) | 一种用于婴幼儿敏感肌肤护理的组合物及其制备方法 | |
CN106377602A (zh) | 一种铁皮石斛复合消毒粉及制备方法和使用方法 | |
CN106822321B (zh) | 伤科黄水在制备治疗毛周角化症的药物中的应用 | |
CN105194330A (zh) | 一种促进伤口愈合的中药组合物及其制备方法 | |
CN106728069B (zh) | 一种治疗烫烧伤的祛腐生肌膏 | |
CN104306707A (zh) | 一种治疗褥疮的药物组合物 | |
CN104623443A (zh) | 治疗皮肤糜烂的中药 | |
CN110882270B (zh) | 一种含有硅基再生医学材料的药物组合物及其制备方法 | |
CN108066466A (zh) | 一种治疗烧烫伤的中药组合物及其制备方法与应用 | |
CN116889585A (zh) | 一种紫草疮愈油、其制备方法和应用 | |
CN105456708A (zh) | 一种用于治疗口唇炎的药物及其制备方法 | |
CN104857229A (zh) | 一种治疗狐臭或汗臭的中药组合物及其制备方法 | |
CN117858715A (zh) | 一种烧烫伤药酊及其制备方法 | |
CN107050298A (zh) | 一种治疗烧烫伤皮损的中药膏配方及制备方法 | |
CN104491104A (zh) | 一种临床护理上用于治疗褥疮的中药组合物 | |
CN110522868A (zh) | 皮肤病治疗液及制备方法 | |
CN117281854A (zh) | 疤痕软散液及其制备方法 | |
CN115607626A (zh) | 褥疮护理药膜及其制备方法 | |
CN113648382A (zh) | 一种速效治疗烧烫伤及感染的组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |